Part 1 and Part 2: Change From Baseline (CFB) in Weight
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function · Source last updated 2026-07-01
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
MEAN
Unit
Kilogram (Kg)
Interval / dispersion
Standard Deviation
Time frame
Baseline (Day 1) and up to approx. 236 weeks
What was measured
Physical examination parameter weight was assessed. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline
Analysis population: Safety population. Only those participants who were measured and analyzed (i.e., contributed to data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints. The "0" participants analyzed represents that data was not collected or available for analysis at that particular time point for the respective Arms/Groups.
Groups in this outcome
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
Participants with Relapsed/Refractory Multiple Myeloma (RRMM) who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and normal/mildly impaired renal function received intravenous (IV) infusion of 2.5 milligram (mg)/kilogram (kg) belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to adverse event (AE), lost to follow-up, death, whichever occurs first.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and severe renal impairment renal function received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and other renal impairment renal function received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and end stage renal disease (ESRD) (not on hemodialysis) received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and ESRD (on hemodialysis) received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
10
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
9
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
4
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
5
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
8
Reported measurements
Baseline (Day 1)
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
10
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
9
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
4
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
5
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
8
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
73.44
19.619
Not reported
Not reported
Not reported
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
68.92
12.143
Not reported
Not reported
Not reported
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
84.03
28.349
Not reported
Not reported
Not reported
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
61.34
15.536
Not reported
Not reported
Not reported
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
68.41
20.296
Not reported
Not reported
Not reported
CFB to Cycle 2 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
9
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
8
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
3
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
5
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
7
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
0.51
2.750
Not reported
Not reported
Not reported
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
0.34
0.870
Not reported
Not reported
Not reported
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
-0.43
0.929
Not reported
Not reported
Not reported
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
-0.22
1.794
Not reported
Not reported
Not reported
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
0.17
0.695
Not reported
Not reported
Not reported
CFB to Cycle 3 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
4
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
5
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
2
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
4
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
7
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
0.38
0.624
Not reported
Not reported
Not reported
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
0.52
1.099
Not reported
Not reported
Not reported
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
-0.15
0.495
Not reported
Not reported
Not reported
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
0.63
1.040
Not reported
Not reported
Not reported
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
-0.89
3.302
Not reported
Not reported
Not reported
CFB to Cycle 4 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
3
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
3
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
2
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
4
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
6
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
-0.80
3.863
Not reported
Not reported
Not reported
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
1.10
0.173
Not reported
Not reported
Not reported
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
-0.75
1.061
Not reported
Not reported
Not reported
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1.18
1.195
Not reported
Not reported
Not reported
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
-0.17
2.967
Not reported
Not reported
Not reported
CFB to Cycle 5 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
3
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
3
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
4
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
6
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
0.07
2.663
Not reported
Not reported
Not reported
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
1.60
0.656
Not reported
Not reported
Not reported
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
0.50
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1.43
1.338
Not reported
Not reported
Not reported
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
0.47
4.575
Not reported
Not reported
Not reported
CFB to Cycle 6 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
3
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
2
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
4
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
5
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1.33
3.889
Not reported
Not reported
Not reported
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
1.45
0.778
Not reported
Not reported
Not reported
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
-0.80
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1.88
4.785
Not reported
Not reported
Not reported
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
-2.88
3.664
Not reported
Not reported
Not reported
CFB to Cycle 7 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
3
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
2
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
2
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
2
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
0.13
2.695
Not reported
Not reported
Not reported
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
2.15
0.212
Not reported
Not reported
Not reported
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
-1.20
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1.95
1.344
Not reported
Not reported
Not reported
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
-2.20
2.970
Not reported
Not reported
Not reported
CFB to Cycle 8 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
3
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
2
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
1
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
0.10
3.843
Not reported
Not reported
Not reported
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
-0.10
3.394
Not reported
Not reported
Not reported
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
-1.40
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
3.00
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
0.00
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to Cycle 9 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
1
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
5.00
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
2.50
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
-1.50
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
3.50
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
0.20
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to Cycle 10 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
1
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
3.30
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
2.60
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
-1.60
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
3.60
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
0.00
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to Cycle 11 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
1
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
3.40
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
2.50
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
-1.70
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
3.00
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
-0.40
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to Cycle 12 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
1
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
3.30
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
2.30
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
-1.70
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
4.50
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
-0.40
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to Cycle 13 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
1
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
2.90
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
2.40
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
-1.80
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
4.80
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
-0.40
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to Cycle 14 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
1
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
5.50
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
2.50
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
-1.60
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
3.00
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
-0.70
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to Cycle 15 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
1
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
6.50
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
2.40
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
-1.40
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
2.00
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
0.00
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to Cycle 16 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
1
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
4.80
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
2.70
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
-1.50
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1.30
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
0.20
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to Cycle 17 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
1
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
3.00
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
2.10
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
-1.60
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1.60
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
-0.20
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to Cycle 18 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
1
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
2.00
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
2.00
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
-1.80
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1.00
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
0.30
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to Cycle 19 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
0
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1.60
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
2.30
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
-1.70
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
0.70
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to Cycle 20 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
0
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
0
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
0
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
0.70
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
0.90
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to Cycle 21 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
0
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
0
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
0
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
0
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1.00
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to Cycle 22 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
0
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
0
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
0
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
0
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1.00
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to Cycle 23 Day 1
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
0
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
0
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
0
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
0
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
2.80
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to Week 07
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
0
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
0
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
0
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
0
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
2.50
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to Week 10
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
0
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
0
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
0
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
0
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
0.00
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to Week 13
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
0
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
1
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
0
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
0
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
0
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
-3.00
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
CFB to End of Treatment (Up to 236 weeks)
Analysis denominator · Participants
Group
Source count
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
4
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
7
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
1
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
2
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
0
Values in Kilogram (Kg) · Interval/dispersion: Standard Deviation
Group
Value
Spread
Lower
Upper
Comment
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
-1.38
4.886
Not reported
Not reported
Not reported
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
0.47
2.856
Not reported
Not reported
Not reported
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
0.00
NA
Not reported
Not reported
Standard Deviation is not evaluable as only a single participant was analyzed.
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
-0.80
1.273
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
spread
19.619
value
73.44
group Id
OG001
spread
12.143
value
68.92
group Id
OG002
spread
28.349
value
84.03
group Id
OG003
spread
15.536
value
61.34
group Id
OG004
spread
20.296
value
68.41
denoms
counts
group Id
OG000
value
10
group Id
OG001
value
9
group Id
OG002
value
4
group Id
OG003
value
5
group Id
OG004
value
8
units
Participants
title
Baseline (Day 1)
categories
measurements
group Id
OG000
spread
2.750
value
0.51
group Id
OG001
spread
0.870
value
0.34
group Id
OG002
spread
0.929
value
-0.43
group Id
OG003
spread
1.794
value
-0.22
group Id
OG004
spread
0.695
value
0.17
denoms
counts
group Id
OG000
value
9
group Id
OG001
value
8
group Id
OG002
value
3
group Id
OG003
value
5
group Id
OG004
value
7
units
Participants
title
CFB to Cycle 2 Day 1
categories
measurements
group Id
OG000
spread
0.624
value
0.38
group Id
OG001
spread
1.099
value
0.52
group Id
OG002
spread
0.495
value
-0.15
group Id
OG003
spread
1.040
value
0.63
group Id
OG004
spread
3.302
value
-0.89
denoms
counts
group Id
OG000
value
4
group Id
OG001
value
5
group Id
OG002
value
2
group Id
OG003
value
4
group Id
OG004
value
7
units
Participants
title
CFB to Cycle 3 Day 1
categories
measurements
group Id
OG000
spread
3.863
value
-0.80
group Id
OG001
spread
0.173
value
1.10
group Id
OG002
spread
1.061
value
-0.75
group Id
OG003
spread
1.195
value
1.18
group Id
OG004
spread
2.967
value
-0.17
denoms
counts
group Id
OG000
value
3
group Id
OG001
value
3
group Id
OG002
value
2
group Id
OG003
value
4
group Id
OG004
value
6
units
Participants
title
CFB to Cycle 4 Day 1
categories
measurements
group Id
OG000
spread
2.663
value
0.07
group Id
OG001
spread
0.656
value
1.60
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG002
spread
NA
value
0.50
group Id
OG003
spread
1.338
value
1.43
group Id
OG004
spread
4.575
value
0.47
denoms
counts
group Id
OG000
value
3
group Id
OG001
value
3
group Id
OG002
value
1
group Id
OG003
value
4
group Id
OG004
value
6
units
Participants
title
CFB to Cycle 5 Day 1
categories
measurements
group Id
OG000
spread
3.889
value
1.33
group Id
OG001
spread
0.778
value
1.45
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG002
spread
NA
value
-0.80
group Id
OG003
spread
4.785
value
1.88
group Id
OG004
spread
3.664
value
-2.88
denoms
counts
group Id
OG000
value
3
group Id
OG001
value
2
group Id
OG002
value
1
group Id
OG003
value
4
group Id
OG004
value
5
units
Participants
title
CFB to Cycle 6 Day 1
categories
measurements
group Id
OG000
spread
2.695
value
0.13
group Id
OG001
spread
0.212
value
2.15
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG002
spread
NA
value
-1.20
group Id
OG003
spread
1.344
value
1.95
group Id
OG004
spread
2.970
value
-2.20
denoms
counts
group Id
OG000
value
3
group Id
OG001
value
2
group Id
OG002
value
1
group Id
OG003
value
2
group Id
OG004
value
2
units
Participants
title
CFB to Cycle 7 Day 1
categories
measurements
group Id
OG000
spread
3.843
value
0.10
group Id
OG001
spread
3.394
value
-0.10
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG002
spread
NA
value
-1.40
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG003
spread
NA
value
3.00
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG004
spread
NA
value
0.00
denoms
counts
group Id
OG000
value
3
group Id
OG001
value
2
group Id
OG002
value
1
group Id
OG003
value
1
group Id
OG004
value
1
units
Participants
title
CFB to Cycle 8 Day 1
categories
measurements
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG000
spread
NA
value
5.00
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG001
spread
NA
value
2.50
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG002
spread
NA
value
-1.50
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG003
spread
NA
value
3.50
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG004
spread
NA
value
0.20
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
1
group Id
OG004
value
1
units
Participants
title
CFB to Cycle 9 Day 1
categories
measurements
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG000
spread
NA
value
3.30
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG001
spread
NA
value
2.60
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG002
spread
NA
value
-1.60
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG003
spread
NA
value
3.60
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG004
spread
NA
value
0.00
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
1
group Id
OG004
value
1
units
Participants
title
CFB to Cycle 10 Day 1
categories
measurements
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG000
spread
NA
value
3.40
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG001
spread
NA
value
2.50
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG002
spread
NA
value
-1.70
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG003
spread
NA
value
3.00
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG004
spread
NA
value
-0.40
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
1
group Id
OG004
value
1
units
Participants
title
CFB to Cycle 11 Day 1
categories
measurements
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG000
spread
NA
value
3.30
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG001
spread
NA
value
2.30
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG002
spread
NA
value
-1.70
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG003
spread
NA
value
4.50
comment
Standard Deviation is not evaluable as only a single participant was analyzed.
group Id
OG004
spread
NA
value
-0.40
denoms
counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
1
group Id
OG004
value
1
units
Participants
title
CFB to Cycle 12 Day 1
denoms
counts
group Id
OG000
value
10
group Id
OG001
value
9
group Id
OG002
value
4
group Id
OG003
value
5
group Id
OG004
value
8
units
Participants
description
Physical examination parameter weight was assessed. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline
dispersion Type
Standard Deviation
groups
description
Participants with Relapsed/Refractory Multiple Myeloma (RRMM) who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and normal/mildly impaired renal function received intravenous (IV) infusion of 2.5 milligram (mg)/kilogram (kg) belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to adverse event (AE), lost to follow-up, death, whichever occurs first.
id
OG000
title
Part 1: Belantamab Mafodotin 2.5 mg/kg (Normal/Mildly Impaired Renal Function)
description
Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and severe renal impairment renal function received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.
id
OG001
title
Part 1: Belantamab Mafodotin 2.5 mg/kg (Severely Impaired Renal Function)
description
Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and other renal impairment renal function received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.
id
OG002
title
Part 1: Belantamab Mafodotin 2.5 mg/kg (Other Renal Function)
description
Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and end stage renal disease (ESRD) (not on hemodialysis) received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.
id
OG003
title
Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)
description
Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and ESRD (on hemodialysis) received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.
id
OG004
title
Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)
param Type
MEAN
population Description
Safety population. Only those participants who were measured and analyzed (i.e., contributed to data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints. The "0" participants analyzed represents that data was not collected or available for analysis at that particular time point for the respective Arms/Groups.
reporting Status
POSTED
time Frame
Baseline (Day 1) and up to approx. 236 weeks
title
Part 1 and Part 2: Change From Baseline (CFB) in Weight
Triangle